AI enables much faster pathology for life-or-death interventions

After training deep neural networks on around 4,000 slide images from around 40 biopsied kidney patients, UCLA engineers have virtually re-stained tissue images for speedier high-accuracy diagnostics than a human histotechnologist could support.  

Turnaround time was especially impressive, as the AI completed in seconds a task that typically requires hours if not days—and because minutes matter in critical lab-reliant procedures like kidney transplant rejections.

What’s more, in clinical practice the high efficiency would translate to substantial savings.

The work is described in a study published by Nature Communications.

Senior author Aydogan Ozcan, PhD, and colleagues concentrated on virtualizing specialized stains from image data produced by the most common stain, hematoxylin and eosin (H&E), because H&E is used in most tissue-staining procedures.

They used label-free autofluorescence tissue images to create perfectly registered training images.

The process “simultaneously generated both the H&E and special stain images with a nanoscopic match in the local coordinates of each virtually stained image pair of our training dataset,” the authors explain.

The resulting technique is highly generalizable, they state, to other “stain-to-stain” image transformations.

“For example, transformations from special stains to H&E or from immunofluorescence to H&E or special stains could be performed using the presented method,” Ozcan and co-authors write. “Our approach allows pathologists to visualize different tissue constituents without waiting for additional slides to be stained with special stains, and we demonstrated it to be effective for the clinical diagnosis of multiple renal diseases.”

Additionally, their innovative technique can be executed on a consumer-grade desktop computer as long as the device has two GPUs. With this simple compute setup, the AI can render diagnostic-quality re-stains in seconds, “saving labor, time [and] chemicals, and can significantly benefit the patient as well as the healthcare system,” the authors comment.

In UCLA’s internal coverage of the development, Ozcan underscores the technique’s potential to eliminate the need for special stains to be performed by histotechnologists.

The heightened speed and accuracy of the AI-enhanced technique, he suggests, eventually may make it a standard step when a pathologist’s fast and accurate diagnosis could enable an immediate lifesaving treatment.

The UCLA coverage is here, and the study is available in full for free.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.